Aeolus Pharmaceuticl
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the… Read more
Aeolus Pharmaceuticl (AOLS) - Total Liabilities
Latest total liabilities as of June 2017: $587.00K USD
Based on the latest financial reports, Aeolus Pharmaceuticl (AOLS) has total liabilities worth $587.00K USD as of June 2017.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aeolus Pharmaceuticl - Total Liabilities Trend (1996–2016)
This chart illustrates how Aeolus Pharmaceuticl's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aeolus Pharmaceuticl Competitors by Total Liabilities
The table below lists competitors of Aeolus Pharmaceuticl ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nowigence Inc.
OTCQB:NOWG
|
USA | $797.32K |
|
Arras Minerals Corp.
OTCQB:ARRKF
|
USA | $668.58K |
|
Cycurion, Inc. Common Stock
PINK:CYCU
|
USA | $20.29 Million |
|
SIEVI CAPITAL (WE3.SG)
STU:WE3
|
Germany | €245.80 Million |
Liability Composition Analysis (1996–2016)
This chart breaks down Aeolus Pharmaceuticl's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aeolus Pharmaceuticl's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aeolus Pharmaceuticl (1996–2016)
The table below shows the annual total liabilities of Aeolus Pharmaceuticl from 1996 to 2016.
| Year | Total Liabilities | Change |
|---|---|---|
| 2016-09-30 | $972.00K | -62.93% |
| 2015-09-30 | $2.62 Million | +31.43% |
| 2014-09-30 | $2.00 Million | +58.21% |
| 2013-09-30 | $1.26 Million | -94.16% |
| 2012-09-30 | $21.59 Million | -15.49% |
| 2011-09-30 | $25.55 Million | -12.41% |
| 2010-09-30 | $29.17 Million | +1382.16% |
| 2009-09-30 | $1.97 Million | -8.76% |
| 2008-09-30 | $2.16 Million | +187.22% |
| 2007-09-30 | $751.00K | -59.34% |
| 2006-09-30 | $1.85 Million | -1.18% |
| 2005-09-30 | $1.87 Million | -19.58% |
| 2004-09-30 | $2.32 Million | -87.20% |
| 2003-09-30 | $18.16 Million | +8.86% |
| 2002-09-30 | $16.68 Million | +461.46% |
| 2001-09-30 | $2.97 Million | +17.15% |
| 2000-09-30 | $2.54 Million | -39.62% |
| 1999-09-30 | $4.20 Million | -48.15% |
| 1998-09-30 | $8.10 Million | -32.50% |
| 1997-09-30 | $12.00 Million | +500.00% |
| 1996-09-30 | $2.00 Million | -- |